Spearman Biotechnology (Shanghai) Co., Ltd. belongs to CBMG Biomedical Group, an American listed company. It is a biomedical high-tech enterprise specializing in clinical application research and technical services of cell biotherapy in China. China is the third professional biological company listed on the Nasdaq capital market. .
The company is located in caohejing Development Zone, Xuhui District, with a research base of 2,400 square meters. The company has a strong management team, perfect clinical research and technical force, and a large number of top medical experts and technical researchers. At the same time, the company maintains close cooperation with leading medical institutions, biomedical companies, clinical trial companies and laboratories at home and abroad to carry out clinical trial cooperation on cell biotherapy methods and new drugs. At present, the company is conducting clinical phase I trials of autologous cell therapy and tumor immune cell therapy for knee degenerative diseases, which is recognized as an advanced and relatively safe and mature cell therapy technology at home and abroad.
With a strong sense of mission to make China's biomedical industry occupy a place in the international competition, Spearman Bio has developed rapidly in just three years since its establishment, built a perfect clinical experiment platform, attracted the attention and intervention of well-known venture capital companies at home and abroad, realized the combination of capital and technology, and is continuing to work hard according to the set goals, striving to become a world-class biomedical enterprise at an early date and make contributions to the health of all mankind.